NCT03234751View on ClinicalTrials.gov

Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

September 24, 2018

Study Completion Date

February 19, 2020

Conditions
Diabetes
Interventions
DRUG

Continous IV infusion of Nesiritide

Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.

DRUG

Hyperinsulinemic euglycemic clamp

48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.

DRUG

Placebo

48 hours of placebo.

Trial Locations (1)

32804

Translational Research Institute for Metabolism and Diabetes, Orlando

All Listed Sponsors
lead

AdventHealth Translational Research Institute

OTHER

NCT03234751 - Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects | Biotech Hunter | Biotech Hunter